相关实验视频

Updated: Jan 11, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

超越PSMA的前列腺癌成像:GRPR,AR和氨基酸痕迹物的应用

Farzana Z Ali¹

¹Department of Molecular and Medical Pharmacology, Division of Nuclear Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.

Diagnostics (Basel, Switzerland)

|November 13, 2025

概括

新的放射性追踪剂在PSMA表达低时为前列腺癌 (PCa) 治疗提供了替代方案. 本综述探讨了胃素释放受体 (GRPR) 连接体,雄激素受体 (AR) 连接体和氨基酸类似物,以改善PCa管理.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射化学放射化学是指辐射化学.

背景情况:

前列腺特异性膜抗原 (PSMA) 向的治疗药物是晚期前列腺癌 (PCa) 的标准.
由于瘤异质性或治疗效应,大约三分之一的转移性割抵抗性PCa (mCRPC) 病变中PSMA表达可能很低或不存在.
对于PSMA下调的机制,如神经内分泌分化或上皮细胞转化为介质细胞转化 (EMT),尚不完全理解.

研究的目的:

对超越PSMA的PCa成像和治疗的新型放射标志物进行审查.
解决关于PSMA下调监管在PCa.的知识差距.
讨论PCa管理的替代性精神分析策略.

主要方法:

对新兴放射性追踪剂的临床前和临床证据的审查.
分析GRPR连接体,AR连接体和氨基酸类型的诊断性能和治疗潜力.
在特定的PCa患者群体 (例如,低PSA,BCR,PSMA阴性疾病) 中评估放射性追踪器的实用性.

主要成果:

针对GRPR的射线追踪器显示高灵敏度 (高达88%) 和特异性 (高达90%) 检测PCa.
-18 (¹⁸F) --5α-二 (FDHT) 在mCRPC PET扫描中显示了98%的真阳性率.
F-fluciclovine显示PSA ≥5的病变检测率为84%,PSA 0.7-1.的病变检测率为62.5%,PSA ≥5的病变检测率为84%.

结论:

新兴的放射性追踪物,如GRPR配体,AR配体和氨基酸类似物,为PCa治疗药物提供了PSMA的有希望的替代品.
这些标记物在特定的患者亚组中具有互补的作用和实用性,包括那些患有PSMA阴性疾病的患者.
多标志物和双准策略是个性化PCa治疗术的未来方向,解决瘤异质性.

关键词:

这就是为什么GRPR是GRPR.聚乙烯/聚乙烯/聚乙烯没有PSMA负面的PSMA.受体受体是受体的受体.炸弹中的炸弹这种药物是fluciclovine.分子成像分子成像技术前列腺癌是前列腺癌.放射性核酸治疗是一种放射性核酸治疗.他们是天文学家.

更多相关视频

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

相关概念视频

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies IV: Magnetic Resonance Imaging

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...